Is JD.com (JD) The Best Chinese Stock to Buy According to Billionaires?
We recently published a list of the 10 Best Chinese Stocks to Buy According to Billionaires. In this article, we are going to take a look at where JD.com, Inc. (NASDAQ:JD) stands against the other Chinese stocks held by billionaires.
The People's Bank of China's (PBoC) monetary easing and government stimulus have lifted the valuations of Chinese equities. A few months ago, many investors were expecting the U.S. economy to be in a better position and Chinese stocks were facing significant regulatory worries. However, the tables have turned with the Chinese economy expected to be in a better position compared to 2024.
Things have taken a wild turn with the U.S. president imposing high tariffs and investors expecting an economic slowdown in the U.S. On the other hand, China's advancement in AI and its capabilities to grow its AI infrastructure have intensified since the launch of DeepSeek's R1 model.
'The U.S. has had a good period, and that's coming to an end because Trump's policies are very anti-economy. China has had a very bad period, but it looks as if it's starting to recover,' Richard Harris, CEO of Port Shelter Investment Management, told CNBC.
Chinese government support for its technology sector has induced much optimism among investors. The Hang Seng Tech Index, which tracks some of the largest Chinese companies listed in Hong Kong, has soared over 21% year-to-date, as of March 25. At the same time, the NASDAQ 100 index, covering the U.S. tech stocks, has plunged over 3.70%. Whereas, the Shanghai Composite Index has risen over 3% compared to a drop of 1.70% in the S&P 500 index.
'Performance of the HSCEI/MSCI China in the past 17 months trended closely to the trajectory a decade ago, making us worry that we might be approaching some correction soon,' analysts at the Bank of America wrote in a report published on March 17.
Harris believes that China's A shares have been quite depressed for some time compared to the U.S. stocks. With valuation improvements and optimism in the tech sector in China, it is a good time to explore Chinese stocks.
A supply chain employee using the company's secure supply chain management software to update their customer's records.
To compile our list of the best Chinese stocks to buy according to billionaires, we looked for the Chinese stocks widely held by billionaires. Data for the number of billionaire investors for each stock was taken from Insider Monkey's database, updated as of Q4 2024. Finally, the 10 best Chinese stocks to buy were ranked in ascending order based on the number of billionaires holding stakes in them. We have also mentioned the number of hedge funds that held these stocks as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
No. of Billionaire Investors: 18
Total Billionaire Stake: $1.82 Billion
No. of Hedge Fund Holders: 78
JD.com, Inc. (NASDAQ:JD) is a top Chinese e-commerce and supply chain company. It operates one of China's largest e-commerce platforms, competing with Alibaba and Pinduoduo. The company also offers logistics, digital solutions, and asset management services to businesses. With operations in logistics and controlling the supply chain, JD differentiates itself from its competitors through a focus on quality and a direct-sales model.
JP Morgan analyst Andre Chang increased the price target on JD from $50 to $55, maintaining an Overweight rating on the shares. Following strong Q4 results, the analysts remain optimistic about the company's future earnings. JD.com, Inc. (NASDAQ:JD) posted a revenue of $147.5 million in Q4 2024, up by 13.4% from a year ago, with full-year revenue up 6.8% to $158.8 billion. The company exceeded full-year revenue estimates by $3.36 billion. JD.com also surpassed the 2024 earnings estimate of $4.10, posting an EPS of $4.29 per share.
Overall JD ranks 2nd on our list of the Chinese stocks to buy according to billionaires. While we acknowledge the potential of JD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks To Invest In According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Trump Says US Won't Agree to Any Uranium Enrichment by Iran
(Bloomberg) -- The US won't allow any uranium enrichment as part of a potential nuclear deal with Iran, President Donald Trump said. Where the Wild Children's Museums Are Billionaire Steve Cohen Wants NY to Expand Taxpayer-Backed Ferry The Economic Benefits of Paying Workers to Move Now With Colorful Blocks, Tirana's Pyramid Represents a Changing Albania At London's New Design Museum, Visitors Get Hands-On Access Trump made the comment in a social media post Monday evening, without elaborating. The US president has regularly signaled that he thinks a deal may be near, and that Iran could face military action if the talks collapse. His post came after an Axios report said US negotiators gave Iran a proposal that would allow limited, low-level enrichment. Iran hasn't commented on the report. Trump has long pledged that Iran won't be allowed a nuclear weapon. He also said last week he told Israeli Prime Minister Benjamin Netanyahu that a military strike on Iran — which could lead to the wider war in the Middle East and push up oil prices — would be 'inappropriate' right now because 'we're very close to a solution.' Netanyahu has said Iran — Israel's arch-enemy — shouldn't be allowed to enrich uranium at all, even to the low levels Tehran says its needs for nuclear power plants and other non-military uses. The Islamic Republic has consistently said it won't accept an agreement with the US that doesn't allow it to enrich uranium to a low level. At the moment, it's processing uranium to a much higher point, almost to the level required for atomic weapons. In addition to the issue of enrichment, Iran says it wants clear assurances of how sanctions would be eased as part of any deal with the US. Washington has not yet been willing to specify how sanctions would be lifted, Iran's Foreign Ministry Spokesman, Esmail Baghaei, said on Monday. --With assistance from Arsalan Shahla. (Adds Axios report in third paragraph.) YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Millions of Americans Are Obsessed With This Japanese Barbecue Sauce Mark Zuckerberg Loves MAGA Now. Will MAGA Ever Love Him Back? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To Will Small Business Owners Knock Down Trump's Mighty Tariffs? ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Prairie Village residents show mixed reactions toward city hall rebuild
PRAIRIE VILLAGE, Kan. — The City of Prairie Village wants to rebuild a new city hall on a former church site. They also want renovate and expand the police department and municipal court at the current building, with a total price around $30 million. Shawnee police in touch with Abarca; missing persons case still active Part of the project includes building the new Build to LEED standards, a framework that's used to build and operate in a sustainable manner, according to Prairie Village's website. Here is the following breakdown of the costs: Land purchase – $4.5 million Police department/municipal court renovations – $7.5 million City hall construction – $18 million The project requires $27 million to be borrowed over 30 years. It will be paid through existing taxes and other existing revenue sources. There are no proposed increases to tax rates, so there will not be a public vote. During the more than an hour long public comment portion of the meeting, some residents were in favor of the new Build and LEED certification. They called it a sustainable investment that will benefit future generations. People who opposed said they're concerned over increased property values, and most of all, it's too expensive of a project for them not to have the ability to vote. One council member responded to some comments. 'Let the residents vote. You have the power, make it happen, what are you afraid of… losing? I know this is probably falling on deaf ears, but just maybe you will decide to do the right thing,' one resident said during the meeting. 'I'm pleased the council is taking a long view with this. We've all benefited from the long line of city leaders and council members who did just that. The LEED Platinum certification would be in the long term best interest of Prairie Village citizens,' another resident said during the meeting. 'If there's uncontrolled spending, then I would like you to quit cherry picking numbers that fit that narrative and tell me where it is,' said Councilman Dave Robinson. Man charged in shooting of Lee's Summit police officer City councilmembers passed a motion to commit to 'Gold' LEED standards for the new city hall but revisit some on the platinum items to add in the future. The design is locked in now. The city council will still need to vote to issue the bonds. That's scheduled for the next council meeting on June 16. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
37 minutes ago
- Yahoo
Addex Convenes Annual General Meeting 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20242. Consultative vote on the Compensation Report for the business year 20243. Appropriation of the results4. Discharge of the members of the Board of Directors and of the Executive Management5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors5.2. Re-election of Raymond Hill as member of the Board of Directors5.3. Re-election of Timothy Dyer as member of the Board of Directors5.4. Re-election of Roger Mills as member of the Board of Directors5.5. Re-election of Jake Nunn as member of the Board of Directors5.6. Re-election of Isaac Manke as member of the Board of Directors6. Re-elections of the members of the Compensation Committee6.1. Re-election of Vincent Lawton as member of the Compensation Committee6.2. Re-election of Raymond Hill as member of the Compensation Committee7. Re-election of the Auditors8. Re-election of the Independent Voting Rights Representative9. Approval of the compensation of the members of the Board of Directors and of the Executive Management9.1. Compensation of the members of the Board of Directors 9.2. Compensation of the members of the Executive Management10. MiscellaneousThe full invitation to the AGM 2025 may be found in the General Meetings section of the Company's website here. About Addex: Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 (0)7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio
